MedVector
MedVector is a privately held U.S. clinical trial technology company whose Prime-Control platform enables treating physicians to host decentralized trial visits at their local practices via a plug-and-play telemedicine device, serving pharma sponsors, CROs, and clinical trial sites.
- Company typePrivate
- Founded2017
- HeadquartersEl Segundo, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What MedVector does
MedVector is a privately held U.S. clinical trial technology company founded around 2017 and headquartered in El Segundo, California, that enables treating physicians to host decentralized clinical trial appointments from their local practices without becoming investigators or triggering new clinical trial sites. The company's core offering is its proprietary Prime-Control Technology platform — a HIPAA-compliant telemedicine system packaged in a shoebox-sized plug-and-play device that is shipped to a subject's local healthcare provider prior to a study visit. The device automatically connects to the appropriate clinical trial site, allowing the principal investigator to virtually monitor the subject face-to-face while a local nurse serves as the PI's delegated "hands" for blood draws, vitals, and other procedures. Critically, source data is entered directly into the EDC at the clinical trial site by the investigator team rather than through MedVector, a design choice the company cites as preserving FDA Electronic Source Data guidance compliance (September 2013), GCP adherence, and the integrity of the trial's regulatory record.
MedVector operates a "first-of-kind HCP Recruitment" go-to-market model, identifying local specialists who should be referring patients to clinical trials but are not, and onboarding them as alternative visit locations for specific protocols. Around this backbone, the company offers a clinical trial site-utility service that allows community physicians to "prescribe" trials as a care option, a Patient Enrollment Expansion Solution, and the physical Turnkey Trial Visits device — all described as facets of the same Prime-Control backbone rather than separate products.
The business model is service-based and enterprise-oriented: MedVector partners with CROs, pharmaceutical sponsors, and patient recruitment companies, with revenue generated by pharma sponsors paying for protocol-specific expansion services and study-specific tests performed at physician offices. Pricing is custom and not publicly disclosed. The company has supplemented its capital base through multiple funding rounds (cumulative disclosed funding of roughly $4.66M across 2018–2024, including approximately $492,000 raised from 227 retail investors via StartEngine equity crowdfunding at a $10 million valuation) and has assembled a senior advisory bench including Craig Lipset (former Pfizer Head of Clinical Innovation, DTRA co-chair) and John Neal (founder/chairman of PCRS Network). Headcount is reported at 1–10 employees and only one named enterprise customer (Novartis) appears in disclosed case material.
MedVector firmographics
Firmographics- Name
- MedVector
- Legal name
- MedVector Corp
- Website
- https://medvector.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MedVector is a privately held U.S. clinical trial technology company whose Prime-Control platform enables treating physicians to host decentralized trial visits at their local practices via a plug-and-play telemedicine device, serving pharma sponsors, CROs, and clinical trial sites.
- Ownership category
- akta.pro rank
MedVector industry classification
Industry- Product category
- Decentralized Clinical Trial Technology
- NAICS
- Offices of Physicians (62111), Home Health Care Services (62161)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
- akta.pro primary industry
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
- akta.pro secondary industries
- Pharmacy/Medication Management & Virtual MTM (Payer-Sponsored) (HLALACAK), Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
Keywords
Where MedVector is headquartered
LocationHeadquarters
- HQ city
- El Segundo
- HQ country
- United States
- HQ region
- North America
Markets served
MedVector business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Clinical Trial Expansion Services for Pharma Sponsors and CROs: MedVector generates revenue by partnering with CROs, pharmaceutical sponsors, and patient recruitment companies to deploy its Prime-Control Technology, expanding subject participation beyond existing clinical trial sites. Revenue model is service-based, paid by pharma sponsors who pay for the trial expansion services. Generators of revenue include study-specific tests performed at physician offices, paid for by Pharma.
- StartEngine Equity Crowdfunding: MedVector conducted a public equity crowdfunding raise on StartEngine, raising over $492,000 from 227 investors at a $10 million valuation with a minimum investment of $495.90. This was a one-time capital raise rather than ongoing revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Custom enterprise engagement - quote-based |
Go-to-market motion1 record
MedVector product offering
Product offeringCore offering
MedVector provides a proprietary telemedicine platform, Prime-Control Technology, that enables clinical trial sites to virtually monitor subjects face-to-face at their local healthcare providers' offices without triggering new clinical trial sites or investigators. MedVector ships a shoebox-sized plug-and-play device to the subject's local HCP so a Principal Investigator (PI) can run the session remotely while the local nurse serves as the PI's "hands" for vitals, blood draws, and procedures. Source data is still entered into the trial site's EDC by the investigator team, preserving Good Clinical Practice (GCP).
Product overview
MedVector is a single-platform clinical trial site-utility, not a multi-module suite. Its offering centers on the proprietary Prime-Control Technology platform, a turnkey telemedicine/HCP-recruitment model in which MedVector ships a shoebox-sized plug-and-play device to a subject's local healthcare provider so a clinical trial site's principal investigator (PI) can virtually monitor the subject face-to-face while the local nurse serves as the PI's "hands." Wrapped around Prime-Control are the MedVector clinical-trial-site-utility service (allowing community physicians to "prescribe" trials as a care option without becoming investigators), the Patient Enrollment Expansion Solution (HIPAA-compliant telemedicine for finding and recruiting diverse patients), the HCP Recruitment service (identifying and onboarding local specialists who should be referring but aren't), and the physical Turnkey Trial Visits device. All of these are facets of the same Prime-Control backbone rather than separate products.
Differentiator
Problem solved
Functional benefit
Brands
- Prime-Control Technology: Proprietary telemedicine platform / embedded software shipped as a shoebox-sized plug-and-play device enabling clinical trial sites to virtually monitor subjects face-to-face at local providers' offices.
Products and services
- Prime-Control Technology Platform Proprietary telemedicine platform that connects a clinical trial site with a subject's local, non-investigator healthcare provider (HCP). MedVector ships a shoebox-sized plug-and-play device to the local HCP, allowing the Principal Investigator (PI) to virtually monitor subjects face-to-face while a local nurse serves as the PI's "hands" for vitals, blood draws, and procedures. Data is entered by the investigator team into the trial site's existing EDC, preserving Good Clinical Practice (GCP) and FDA-compliant source data location. For pharmaceutical sponsors and CROs seeking to expand enrollment without triggering new clinical trial sites or new investigators.
- HCP Recruitment Service First-of-kind service offering that identifies and onboards local specialists who should be referring patients to clinical trials but aren't, then activates them as alternative MedVector visit locations for specific qualifying protocols. Coordinates all logistics between the clinical trial site and alternative locations; training is provided at clinical trial sites with no training required at alternative locations. For pharmaceutical sponsors and CROs seeking to expand the referring physician pool for trial enrollment.
- Turnkey Trial Visits Device Physical plug-and-play telemedicine device shipped to a subject's local healthcare provider prior to a trial appointment. The unit automatically connects to the appropriate clinical trial site, allowing the Principal Investigator to control the entire live session as if co-located with the subject. The local nurse performs generic procedures (blood draws, vital signs) under the PI's delegated authority. The hardware underpinning MedVector's Prime-Control platform.
- Patient Enrollment Expansion Solution HIPAA-compliant, plug-and-play telemedicine solution for clinical trials that provides tools for finding and recruiting patients, collecting data, and performing analysis across dosage forms including pills, sprays, inhalers, creams, drops, and self-injectable medications. A Novartis case study demonstrated recruitment completed in seven weeks. For pharmaceutical sponsors and CROs seeking faster, more diverse enrollment.
Companies that use MedVector
Customer profileIdeal customer profiles3 records
MedVector technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
MedVector partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
MedVector competitors and assessment
Company assessmentDirect peers
- ObvioHealth: Fully decentralized clinical trial platform combining telehealth, connected devices, and home-based nurse visits for sponsors. Comparable as a DCT vendor competing for the same hybrid visit and remote monitoring budgets.
- Curebase: Decentralized clinical trial software platform enabling sponsors to run studies in participants' homes with connected devices and remote coordinators. Comparable to MedVector as a competing DCT platform for pharma/CRO customers.
- Science 37: Decentralized clinical trial platform offering telehealth, in-home nurse visits, and connected devices for remote trial conduct. Directly comparable to MedVector as a DCT infrastructure player; the two compete for the same pharma/CRO sponsors seeking remote visit capabilities.
- THREAD Research: DCT and eCOA platform supporting decentralized study execution, remote visits, and connected device integrations. Comparable as a competing DCT infrastructure provider in the same pharma/CRO market.
- Medable: Patient-centric DCT platform providing eConsent, eCOA, telehealth, and remote data capture. Comparable to MedVector as a competing DCT infrastructure vendor targeting pharma sponsors and CROs.
Broad incumbents
- Veeva Systems: Enterprise cloud software provider for the life sciences industry, including CTMS, EDC, and eTMF used by clinical trial sponsors and CROs. Comparable as an adjacent incumbent whose ecosystem decisions shape DCT adoption and integration paths.
- IQVIA: Global CRO and clinical technology services provider with a dedicated decentralized clinical trial practice. Comparable as a broad incumbent offering site-less and hybrid trial services to pharma sponsors.
- Signant Health: Clinical trial technology provider offering eCOA, eConsent, patient engagement, and decentralized trial solutions. Comparable as an incumbent DCT/eCOA vendor competing for shared sponsor budgets.
- Clario: Large clinical trial technology vendor offering eCOA, cardiac safety, imaging, and decentralized trial solutions. Comparable as a broader incumbent offering overlapping DCT/remote visit capabilities to the same pharma/CRO buyers.
Emerging players
- Florence Healthcare: Clinical trial site enablement platform providing eRegulatory, eISF, and remote site connectivity tools. Comparable as an emerging enabler focused on site-side workflow, overlapping with MedVector's site-preserving positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
MedVector social profiles
Digital presenceMedVector compliance and trust
Trust signalCompliance3 records
MedVector financial estimates
Financial estimateRevenue estimate
Valuation estimate
MedVector leadership team
Management profileNumber of profiles
Profiles12 records
MedVector subsidiaries and ownership
Company hierarchySubsidiaries1 record
MedVector funding detail
Funding detailFunding overview
Funding rounds6 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MedVector M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MedVector
What does MedVector do?
MedVector provides a proprietary telemedicine platform, Prime-Control Technology, that enables clinical trial sites to virtually monitor subjects face-to-face at their local healthcare providers' offices without triggering new clinical trial sites or investigators. MedVector ships a shoebox-sized plug-and-play device to the subject's local HCP so a Principal Investigator (PI) can run the session remotely while the local nurse serves as the PI's "hands" for vitals, blood draws, and procedures. Source data is still entered into the trial site's EDC by the investigator team, preserving Good Clinical Practice (GCP).
Is MedVector a public or private company?
MedVector is a private company. It is classified as venture growth investor backed and is currently operating.
When was MedVector founded?
MedVector was founded in 2017. It employs 1 to 10 people.
Where is MedVector based?
MedVector is headquartered in El Segundo, United States, in the North America region.
How does MedVector make money?
Two revenue lines are on record. Clinical Trial Expansion Services for Pharma Sponsors and CROs are the primary driver. The others are startEngine Equity Crowdfunding.
Who are MedVector's main competitors?
Direct peers on record are ObvioHealth, Curebase, Science 37, THREAD Research and Medable. Broad incumbents are Veeva Systems, IQVIA, Signant Health and Clario. Florence Healthcare is listed as an emerging player.
Does MedVector have an API?
No public API is recorded for MedVector.
What industry is MedVector in?
MedVector's product category is Decentralized Clinical Trial Technology. Its primary akta.pro industry code is HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity), with a secondary code of HLALACAK, Pharmacy/Medication Management & Virtual MTM (Payer-Sponsored). Its NAICS code is 62111 and its SIC code is 8011.